• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors)2 / 20103 / 2010 AACR_Immunomodulatory Activity of SGI-110

2010 AACR_Immunomodulatory Activity of SGI-110

25 November 2010/in 2010, Guadecitabine (SGI-110) – (Hematological Malignancies and Solid Tumors), Products

2010 AACR_Immunomodulatory Activity of SGI-110

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2010-11-25 16:42:062016-11-25 16:42:252010 AACR_Immunomodulatory Activity of SGI-110

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: 2010 AACR_Immunomodulatory Activity of SGI-110 Link to: 2010 AACR_Immunomodulatory Activity of SGI-110 2010 AACR_Immunomodulatory Activity of SGI-110 Link to: Woodhead et al. “Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design.” Journal of Medicinal Chemistry 53, no. 16 2010: 5956–5969. DOI: 10.1021/jm100060b. Link to: Woodhead et al. “Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design.” Journal of Medicinal Chemistry 53, no. 16 2010: 5956–5969. DOI: 10.1021/jm100060b. Woodhead et al. “Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone...
Scroll to top Scroll to top Scroll to top